Rani Therapeutics Holdings (RANI) Total Current Liabilities (2020 - 2026)

Rani Therapeutics Holdings' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $13.9 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 31.17% year-over-year to $13.9 million in Q1 2026; TTM through Mar 2026 was $13.9 million, a 31.17% decrease from a year earlier, with the FY2025 full-year figure at $12.7 million, down 36.31% from the prior year.
• Total Current Liabilities advanced to $13.9 million in Q1 2026 per RANI's latest filing, from $12.7 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $20.6 million in Q2 2025 and bottomed at $4.2 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $12.7 million (2025), against an average of $12.0 million.
• Across the five-year window, Total Current Liabilities sank 42.82% in 2022 and soared 189.12% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $4.8 million in 2022, then jumped by 65.92% to $8.0 million in 2023, then surged by 148.98% to $19.9 million in 2024, then sank by 36.31% to $12.7 million in 2025, then gained by 9.36% to $13.9 million in 2026.
• Per Business Quant, the three latest RANI Total Current Liabilities figures stand at $13.9 million (Q1 2026), $12.7 million (Q4 2025), and $19.1 million (Q3 2025).